1 Erythropoiesis is regulated by microenvironmental factors from the 2 vasculature. Enhanced erythropoiesis, which occurs under stress or 3 during development, amplifies erythroid cells to meet the demand of 4 red blood cells. This process uncouples cell division and 5 differentiation, thus the accumulated erythroid cells remain 6 undifferentiated in the vasculature. However, little is known about how 7 vascular endothelial cells (ECs) regulate erythropoiesis. Here we 8 identified that human umbilical vein endothelial cells (HUVECs) keep 9 erythroid cells undifferentiated and amplify their number. We 10 determined that HUVECs amplif y erythroid cells via secreted 11 angiocrine factors. The expression profile of these factors suggested 12 that they resemble macrophage-crines for enhanced erythropoiesis . 13 Molecularly, HUVECs mediate the activation of ERK signaling. These 14 data indicate that angiocrine factors from HUVECs enhance 15 erythropoiesis via the amplification of undifferentiated erythroid cells. 16 Our study contributes to the ultimate goal of harnessing erythropoiesis 17 to replace blood transfusions. 18 19 4 1 2
nations-help/blood-needs-blood-supply.html).
The source of these 8 transfusions has depended on blood donors, but more stable sources are 9 required for the anticipated growth in demand (Batta, 2016) . One alternative 10 is stem cells, which can be proliferated to high numbers that pro duce the 11 needed volume (Chung, 2017; Doulatov, 2013; Kinney, 2019; Orkin, 2008) . 12 However, limited understanding of erythropoiesis has prevented the 13 production of clinically relevant quantities of erythrocytes (Fang, 2016; Wei, 14 2019). 15 16 8 that differentiation capacity could be restored . These data demonstrate that 1 HUVECs amplify erythroid cells by keeping them undifferentiated . 2 3 Angiocrine factors from HUVEC s amplify erythroblasts 4 To assess whether cell-cell interactions are required for the enhanced 5 amplification of erythroid cells, we used a transwell assay, where the media 6 and secreted factors could be exchanged but direct HUVEC contact was 7 prevented. We found an increase in erythroid cells in the transwell setting 8 ( fig. 3 ), suggesting that secreted angiocrine factors are involved in the 9 erythroid amplification. To determine the angiocrine factors produced by 10 HUVECs, we conducted an RNA-seq analysis for the genes that encode 
Erythropoiesis enhancing factors (EEFs) include classical hematopoietic 14
cytokines and morphogens whose role s are validated in erythropoiesis 15 (Paulson, 2011) . Recent studies proved that both OP9 (Trakarnsanga, 16 were included among EEFs, whose expressions were not detected in secreted by HUVECs amplify erythroid cells, suggesting a possible 8 mechanism to produce red blood cells in vitro. 9 
10
ERK signaling mediates erythroid commitment of hematopoietic progenitor 11 cells at the initial phase of erythropoiesis , but its role in the subsequent 12 phases of erythropoiesis is not clear (Guihard, 2010) . We demonstrated that 13
ERK signaling amplifies erythroid cells through angiocrine factors from 14
HUVECs. Instead of other erythropoiesis factors , such as EPO (Kuhrt, 15 2015), SCF (Comazzetto, 2019) or glucocorticoids (Narla, 2011), HUVECs 16 produce angiocrine factors in common with those from macrophages to 17 enhance erythropoiesis (Lopez-Yrigoyen, 2019; Seu, 2017). One study 18
showed the contribution of cell-cell contacts between murine hemangioma-derived ECs and erythropoiesis. However, we did not find 1 these contacts to be a factor with HUVECs. ( Ohneda, 1997) . To conclude, 2 our findings suggest that angiocrine factors could enhance erythropoiesis 3 from either donor-derived or hPSC-derived hematopoietic progenitor cells. We are grateful to Alina Li and Takafumi Mano for their technical assistance 4 and Dr. Daisuke Okuzaki for the RNA-seq analysis. We would also like to 5 thank Ms. Harumi Watanabe for providing administrative assistance and Dr. 6 Peter Karagiannis for reading and editing the paper. The authors declare they have no competing financial interests. 
Contact for Reagent and Resource Sharing 11
Further information and requests for resources and reagents should be 12 directed to and will be fulfilled by the Lead Contact, Ryohichi Sugimura 13 (ryohichi.sugimura@gmail.com ). https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE138104 12 13 Method details 14 hPSC culture 15 The maintenance of hPSCs was done using iMatrix-511 (Matrixome) in other day, and the cells were passaged as single cells every 7 days using 1 TrypLE Express (Life technologies). and Giemsa stains, washed with water, air dried, and mounted, followed by Anti-pERK (#4370), anti-ERK (#4695) and anti-beta-actin (#4970) were 9 purchased from Cell Signaling Technology. 10 11 
Western blot 12
Equal amounts of protein extracted from K562 cells were subjected to 13 SDS-PAGE in Tris-Glycine buffer and transferred to PVDF membranes. The 14 membrane was blocked with 5% Skim milk in Tris-buffered saline containing 15 0.1% Tween-20 (TBS-T) for 1 hour at room temperature and probed with the 16 appropriate primary antibody (1:1,000, anti-pERK, ERK or beta-actin 17 antibody) overnight at room temperature. After washing with TBS-T, the 1 membrane was incubated with the appropriate secondary antibody 2 (anti-rabbit IgG HRP-linked antibody (1:1,000, cell signaling)) for 1 hour at 3 room temperature. After washing with TBS-T, the membrane was incubated 4
with West Femto super signal reagent (Thermo scientific), and the specific 5 proteins were visualized with LAS-4000 (GE healthcare). 
Statistics and source data 7
Statistical analyses wer e done with t-test. We used Microsoft Excel for 8 calculations and expressed the results as the means ± s.d. The source data 9 for each graph is available in the supplementary tables. 
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